AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9738607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiologist alone
Number of subjects: 1716
Study 9738607 — intervention group
Group type: COMPARATOR
Intervention: Generalist alone
Number of subjects: 1716
Study 7816008 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous calcitriol (IVC)
Number of subjects: 10
Study 7816008 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcitriol (ORC)
Number of subjects: 10
Study 3281679 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (400 mg t.i.d. for type II patients, 250 mg t.i.d. for type IV patients)
Number of subjects: 130
Study 3281679 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (400 mg t.i.d. for type II patients)
Number of subjects: 130
Study 3281679 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (after 16-week follow-up)
Number of subjects: 130
Study 3281679 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after 16-week follow-up)
Number of subjects: 130
Study 31141553 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with at least two symptoms of iNPH (n = 117)
Number of subjects: 673
Study 31141553 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals aged 80 years and older
Number of subjects: 673
Study 31141553 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals aged 65-79 years
Number of subjects: 673
Study 31141553 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 673
Study 31141553 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 673
Study 31141553 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis according to Japanese guidelines
Number of subjects: 673
Study 29028517 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 60
Study 29028517 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 60
Study 29028517 — intervention group
Group type: COMPARATOR
Intervention: Healthy Volunteers
Number of subjects: 60
Study 25413485 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp nerve blocks
Number of subjects: 32
Study 25413485 — intervention group
Group type: COMPARATOR
Intervention: IV analgesia (piritramide 7.5 mg IV, plus oral metamizole)
Number of subjects: 32
Study 25413485 — intervention group
Group type: COMPARATOR
Intervention: Cold-air analgesia
Number of subjects: 32
Study 22076808 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency (1 Hz) rTMS for 20 min on the left dorsolateral prefrontal cortex
Number of subjects: 11
Study 22076808 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 11
Study 22111896 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) and cyclo-oxygenase-2 (COX-2) inhibitor celecoxib with progressive resistance training (PRT) and essential amino acids high in leucine.
Number of subjects: 21
Study 22111896 — intervention group
Group type: COMPARATOR
Intervention: Eicosapentaenoic acid (EPA) and cyclo-oxygenase-2 (COX-2) inhibitor celecoxib.
Number of subjects: 21
Study 18579384 — intervention group
Group type: EXPERIMENTAL
Intervention: Physilog measurements on tar surface
Number of subjects: 16
Study 18579384 — intervention group
Group type: EXPERIMENTAL
Intervention: Physilog measurements on grass surface
Number of subjects: 16
Study 18579384 — intervention group
Group type: EXPERIMENTAL
Intervention: Physilog measurements on stones surface
Number of subjects: 16
Study 18579384 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-visit ICC for all surfaces
Number of subjects: 16
Study 18579384 — intervention group
Group type: EXPERIMENTAL
Intervention: Coefficient of variation (CV) for gait parameters
Number of subjects: 16
Study 18579384 — intervention group
Group type: EXPERIMENTAL
Intervention: Bland and Altman Plots, SEM and SDC
Number of subjects: 16
Study 18579384 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall conclusion on Physilog
Number of subjects: 16
Study 16841563 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (10-15 mg/day)
Number of subjects: 103
Study 16841563 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (9-15 mg/day)
Number of subjects: 103
Study 12581571 — intervention group
Group type: EXPERIMENTAL
Intervention: GI ‐‐> VC regimen (gemcitabine 1000 mg/m² + ifosfamide 1500 mg/m² followed by vinorelbine 25 mg/m² + cisplatin 100 mg/m²)
Number of subjects: 400
Study 12581571 — intervention group
Group type: EXPERIMENTAL
Intervention: VC ‐‐> GI regimen (vinorelbine 25 mg/m² + cisplatin 100 mg/m² followed by gemcitabine 1000 mg/m² + ifosfamide 1500 mg/m²)
Number of subjects: 400
Study 12581571 — intervention group
Group type: EXPERIMENTAL
Intervention: VC regimen (vinorelbine 25 mg/m² + cisplatin 100 mg/m²)
Number of subjects: 400
Study 12581571 — intervention group
Group type: EXPERIMENTAL
Intervention: GC regimen (gemcitabine 1400 mg/m² + cisplatin 100 mg/m²)
Number of subjects: 400
Study 12581571 — intervention group
Group type: COMPARATOR
Intervention: VC regimen
Number of subjects: 400
Study 12581571 — intervention group
Group type: COMPARATOR
Intervention: GI ‐‐> VC regimen
Number of subjects: 400
Study 12581571 — intervention group
Group type: EXPERIMENTAL
Intervention: VC and GC regimens
Number of subjects: 400
Study 11127169 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower gastrointestinal symptoms reported by participants during semi-structured physician interviews.
Number of subjects: 745
Study 11127169 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation behaviour regarding lower gastrointestinal symptoms.
Number of subjects: 745
Study 11127169 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation behaviour for significant new onset symptoms (rectal bleeding, abdominal pain, change in bowel habit).
Number of subjects: 745
Study 8737130 — intervention group
Group type: EXPERIMENTAL
Intervention: sparfloxacin 200 mg once daily for 5 days following a loading dose of 400 mg on day 1
Number of subjects: 382
Study 8737130 — intervention group
Group type: COMPARATOR
Intervention: cefuroxime axetil 250 mg twice daily for 8 days
Number of subjects: 382
Study 8737130 — intervention group
Group type: EXPERIMENTAL
Intervention: sparfloxacin
Number of subjects: 382
Study 8737130 — intervention group
Group type: COMPARATOR
Intervention: cefuroxime axetil
Number of subjects: 382
Study 1317697 — intervention group
Group type: EXPERIMENTAL
Intervention: preoperative etoposide‐platinum (EP) chemotherapy‐surgery‐postoperative EP
Number of subjects: 27
Study 1317697 — intervention group
Group type: COMPARATOR
Intervention: surgery‐postoperative mediastinal irradiation (SRT)
Number of subjects: 27
Study 4025120 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG Minnesota Q-QS codes
Number of subjects: 692
Study 30843462 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraph inclinometer (AGincl)
Number of subjects: 10
Study 29632222 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin use
Number of subjects: 134
Study 29632222 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure control
Number of subjects: 134
Study 29632222 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol management
Number of subjects: 134
Study 29632222 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking screening and counseling
Number of subjects: 134
Study 29632222 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite measure (ABCs targets)
Number of subjects: 134
Study 29632222 — intervention group
Group type: COMPARATOR
Intervention: Aspirin use (solo practices)
Number of subjects: 134
Study 29632222 — intervention group
Group type: COMPARATOR
Intervention: Composite measure (solo practices)
Number of subjects: 134
Study 26443196 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel napadisilate 75 mg
Number of subjects: 121
Study 26443196 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel bisulfate 75 mg
Number of subjects: 121
Study 24532997 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 200 mg once daily
Number of subjects: 40
Study 24532997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23742030 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg bilastine
Number of subjects: 20
Study 23742030 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg bilastine
Number of subjects: 20
Study 23742030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23742030 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg bilastine
Number of subjects: 20
Study 20008947 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (high dose, 300 mg every 2 weeks)
Number of subjects: 1065
Study 20008947 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (medium dose, 405 mg every 4 weeks)
Number of subjects: 1065
Study 20008947 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (low dose, 150 mg every 2 weeks)
Number of subjects: 1065
Study 20008947 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (very low dose, 45 mg every 4 weeks)
Number of subjects: 1065
Study 20008947 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral olanzapine
Number of subjects: 1065
Study 20008947 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine long-acting injection (all doses combined)
Number of subjects: 1065
Study 20008947 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (high dose)
Number of subjects: 1065
Study 20008947 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (medium dose)
Number of subjects: 1065
Study 20008947 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (low dose)
Number of subjects: 1065
Study 20008947 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (very low dose)
Number of subjects: 1065
Study 20008947 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine long-acting injection and oral olanzapine
Number of subjects: 1065
Study 20008947 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection
Number of subjects: 1065
Study 18439689 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial tonsillectomy (PT) with scalpel
Number of subjects: 96
Study 18439689 — intervention group
Group type: COMPARATOR
Intervention: Total classical tonsillectomy (TT)
Number of subjects: 96
Study 16171488 — intervention group
Group type: EXPERIMENTAL
Intervention: Oronasopharyngeal suction
Number of subjects: 140
Study 16171488 — intervention group
Group type: COMPARATOR
Intervention: No suction
Number of subjects: 140
Study 12902571 — intervention group
Group type: EXPERIMENTAL
Intervention: Podophyllotoxin 0.5% solution
Number of subjects: 358
Study 12902571 — intervention group
Group type: EXPERIMENTAL
Intervention: Podophyllotoxin 0.15% cream
Number of subjects: 358
Study 12902571 — intervention group
Group type: COMPARATOR
Intervention: Podophyllin
Number of subjects: 358
Study 12902571 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 358
Study 12902571 — intervention group
Group type: EXPERIMENTAL
Intervention: Podophyllotoxin solution
Number of subjects: 358
Study 12902571 — intervention group
Group type: EXPERIMENTAL
Intervention: Podophyllotoxin cream
Number of subjects: 358
Study 10343591 — intervention group
Group type: EXPERIMENTAL
Intervention: B-technique of Regnault
Number of subjects: 81
Study 10343591 — intervention group
Group type: EXPERIMENTAL
Intervention: Eren technique
Number of subjects: 81
Study 10343591 — intervention group
Group type: EXPERIMENTAL
Intervention: Frey technique
Number of subjects: 81
Study 10343591 — intervention group
Group type: EXPERIMENTAL
Intervention: Free nipple-areola graft
Number of subjects: 81
Study 7594445 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drug treatment
Number of subjects: 7
Study 2117741 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous, 24-hour nasogastric alimentation (group 1)
Number of subjects: 19
Study 2117741 — intervention group
Group type: COMPARATOR
Intervention: Overnight, 12-hour nasogastric infusions plus daytime oral feedings (group 2)
Number of subjects: 19
Study 2117741 — intervention group
Group type: COMPARATOR
Intervention: Oral feedings alone (group 3)
Number of subjects: 19
Study 7004250 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.3 mg
Number of subjects: 25
Study 7004250 — intervention group
Group type: COMPARATOR
Intervention: Morphine 7.5 mg
Number of subjects: 25
Study 7004250 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 25
Study 31942691 — intervention group
Group type: EXPERIMENTAL
Intervention: Contiguous state residents obtaining abortions in Georgia (n=4216)
Number of subjects: 752227
Study 31942691 — intervention group
Group type: COMPARATOR
Intervention: Georgia residents obtaining abortions (n=29,264)
Number of subjects: 752227
Study 31942691 — intervention group
Group type: EXPERIMENTAL
Intervention: Contiguous state residents
Number of subjects: 752227
Study 29914012 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin application (CA)
Number of subjects: 30
Study 29914012 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC)
Number of subjects: 30
Study 29914012 — intervention group
Group type: COMPARATOR
Intervention: Combined remote ischemic conditioning with capsaicin application (Comb)
Number of subjects: 30
Study 29914012 — intervention group
Group type: COMPARATOR
Intervention: Remote effect of capsaicin application (REC)
Number of subjects: 30
Study 28630358 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSVΔG‐ZEBOV‐GP vaccine
Number of subjects: 40
Study 28630358 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 40
Study 26372054 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional items (negatively valenced and arousing)
Number of subjects: 0
Study 26372054 — intervention group
Group type: COMPARATOR
Intervention: Neutral items
Number of subjects: 0
Study 23190417 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral position (RLP)
Number of subjects: 20
Study 23190417 — intervention group
Group type: COMPARATOR
Intervention: Left lateral position (LLP)
Number of subjects: 20
Study 22007005 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD Internet portal intervention
Number of subjects: 49
Study 18571875 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated CD and primary care during the index treatment episode
Number of subjects: 598
Study 18571875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing medical care (2-10 primary care visits) in the 5 years following intake
Number of subjects: 598
Study 18571875 — intervention group
Group type: COMPARATOR
Intervention: Substance abuse-related medical conditions (SAMCs)
Number of subjects: 598
Study 16781291 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir single-dose (1500 mg once)
Number of subjects: 701
Study 16781291 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir single-day (750 mg twice a day for 1 day)
Number of subjects: 701
Study 16781291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701
Study 12679675 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative hydrocortisone irrigation
Number of subjects: 20
Study 12679675 — intervention group
Group type: COMPARATOR
Intervention: Control (no hydrocortisone irrigation)
Number of subjects: 20
Study 10719296 — intervention group
Group type: EXPERIMENTAL
Intervention: Dust mite antigen (Dermatophagoides farinae)
Number of subjects: 12
Study 10719296 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin (Escherichia coli 026:B6)
Number of subjects: 12
Study 10719296 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study 1313746 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg sumatriptan
Number of subjects: 0
Study 1313746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3893106 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) - prednisone
Number of subjects: 246
Study 3893106 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (Aza) - prednisone - antilymphocyte globulin
Number of subjects: 246
Study 31299013 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonstudy oral PrEP use
Number of subjects: 195
Study 31299013 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PrEP users
Number of subjects: 195
Study 31299013 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of oral PrEP after study completion
Number of subjects: 195
Study 28350282 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-based rehabilitation (m-Health system)
Number of subjects: 118
Study 28350282 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 118
Study 27266340 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (Se) supplementation for 30 days
Number of subjects: 36
Study 27266340 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (Se) supplementation
Number of subjects: 36
Study 24825486 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release methylphenidate (MPH-SR)
Number of subjects: 110
Study 24825486 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 110
Study 23043755 — intervention group
Group type: EXPERIMENTAL
Intervention: CoSeal® (sealant group)
Number of subjects: 216
Study 23043755 — intervention group
Group type: COMPARATOR
Intervention: Sutures/staples (control group)
Number of subjects: 216
Study 20008679 — intervention group
Group type: EXPERIMENTAL
Intervention: AATAAC‐2 assessment after viewing AAC videos
Number of subjects: 330
Study 20008679 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing AAC videos with different gender combinations and device types
Number of subjects: 330
Study 20008679 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-way interaction of familiarity, gender, and type of device
Number of subjects: 330
Study 18593766 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women with PCOS
Number of subjects: 62
Study 18593766 — intervention group
Group type: COMPARATOR
Intervention: Obese PCOS women
Number of subjects: 62
Study 18593766 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-weight women with PCOS
Number of subjects: 62
Study 18593766 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-weight PCOS and controls
Number of subjects: 62
Study 18593766 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups during hyperinsulinemia
Number of subjects: 62
Study 15911816 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (SSRI) for 2 weeks
Number of subjects: 14
Study 15911816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 12240793 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg/day for 4 weeks
Number of subjects: 240
Study 12240793 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 240
Study 12240793 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 240
Study 10406816 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockade therapy
Number of subjects: 268
Study 8884862 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraflo II heparin-coated circuit
Number of subjects: 40
Study 8884862 — intervention group
Group type: COMPARATOR
Intervention: Uncoated standard circuit
Number of subjects: 40
Study 1363731 — intervention group
Group type: EXPERIMENTAL
Intervention: ALO 2145 1%
Number of subjects: 38
Study 1363731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 6339595 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutimelan 8-15 regimen (DTM 8-15): 7 mg of prednisolone acetate and 4 mg of prednisolone alcohol at 8 A.M., 15 mg of cortisone acetate and 3 mg of prednisolone alcohol at 3 P.M., placebo at 8 P.M.
Number of subjects: 8
Study 6339595 — intervention group
Group type: COMPARATOR
Intervention: Placebo at 8 A.M., 15 mg of cortisone acetate and 3 mg of prednisolone alcohol at 3 P.M., 7 mg of prednisolone acetate and 4 mg of prednisolone alcohol at 8 P.M. (Rx 15-20).
Number of subjects: 8
Study 31272868 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived MSCs combined with biphasic calcium phosphate
Number of subjects: 39
Study 29862925 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic online treatment
Number of subjects: 0
Study 26800411 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, nurse-delivered interventions (video and printed education) based on nurse's risk assessment and patient's perception of risk.
Number of subjects: 91
Study 26800411 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 91
Study 24638270 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose-fractionation (LD) group, total doses of 55 Gy and 44 Gy in 22 fractions to PTV1 and PTV2, respectively.
Number of subjects: 53
Study 24638270 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose-fractionation (HD) group, total doses of 66 Gy and 55 Gy in 22 fractions to PTV1 and PTV2, respectively.
Number of subjects: 53
Study 22055739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 0
Study 22055739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20485978 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming group (circulating-water mattress at 37 degrees centigrade)
Number of subjects: 40
Study 20485978 — intervention group
Group type: COMPARATOR
Intervention: Control group (no warming)
Number of subjects: 40
Study 20485978 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 20485978 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming group
Number of subjects: 40
Study 20485978 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 17682105 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin
Number of subjects: 134
Study 17682105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 15930528 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS
Number of subjects: 131
Study 15930528 — intervention group
Group type: COMPARATOR
Intervention: autograft
Number of subjects: 131
Study 12107606 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg BDP as two inhalations from 50‐microg/actuation strength
Number of subjects: 30
Study 12107606 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg BDP as one inhalation from 100‐microg/actuation strength
Number of subjects: 30